ReviewFrontiers in immunology2025
Research progress on the induction of immunogenic cell death in tumor immunotherapy using a sonodynamic therapy nanoparticle delivery system.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in ultrasound-activated nano-sonosensitizers for cancer treatment: a systematic review and meta-analysis.Ultrasonics sonochemistry · 2026Pooled it
- Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- Sonodynamic Therapy-Enhanced Immunotherapy for Triple-Negative Breast Cancer: Mechanistic Advances, Nanoplatform Strategies, and Clinical Prospects.Molecular imaging and biology · 2026Review
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ICD is critical for enhancing antitumor immune responses in tumor immunotherapy. SDT employs ultrasound to activate Sonosensitizers, generating ROS that induce cytotoxic tumor cell death and trigger ICD through the release of DAMPs. However, standalone SDT faces challenges such as limited Sonosensitizers accumulation and poor tissue specificity. Nanoparticle-mediated SDT addresses these limitations by improving Sonosensitizers delivery, tumor targeting, and biocompatibility. This review explores how nanotechnology enhances SDT to induce ICD, focusing on its integration with chemotherapy and immunotherapy to achieve synergistic antitumor effects. We highlight recent advancements in multifunctional nanoplatforms that optimize ROS production, reprogram the tumor microenvironment, and enhance immune activation. By overcoming the constraints of conventional therapies, nanoparticle-mediated SDT offers a promising strategy for precise, effective, and low-toxicity tumor immunotherapy, with potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.